REFERENCES
1. Pan YX, Fu YZ, Hu DD, et al. Stereotactic Body radiotherapy vs. radiofrequency ablation in the treatment of hepatocellular carcinoma: a meta-analysis. Front Oncol 2020;10:1639.
2. Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: a meta-analysis and systemic review. Radiother Oncol 2018;129:123-9.
3. Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 2021;74:2342-52.
4. Yamashita H, Onishi H, Murakami N, et al. Japanese Radiological Society multi-institutional SBRT study group (JRS-SBRTSG). Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res 2015;56:561-7.
5. Sapisochin G, Barry A, Doherty M, et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 2017;67:92-9.
6. Mastrocostas K, Fischer S, Munoz-Schuffenegger P, et al. Radiological tumor response and histopathological correlation of hepatocellular carcinoma treated with stereotactic body radiation therapy as a bridge to liver transplantation. Abdom Radiol (NY) 2021;46:1572-85.
7. Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity. JHEP Rep 2022;4:100498.
8. Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase ii study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460-8.
9. Mendiratta-Lala M, Masch W, Shankar PR, et al. Magnetic resonance imaging evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: long term imaging follow-up. Int J Radiat Oncol Biol Phys 2019;103:169-79.
10. Mendiratta-Lala M, Gu E, Owen D, et al. Imaging findings within the first 12 months of hepatocellular carcinoma treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2018;102:1063-9.
11. Jiao Y, Cao F, Liu H. Radiation-induced cell death and its mechanisms. Health Phys 2022;123:376-86.
12. Mendiratta-Lala M, Masch W, Owen D, et al. Natural history of hepatocellular carcinoma after stereotactic body radiation therapy. Abdom Radiol (NY) 2020;45:3698-708.
13. Mendiratta-Lala M, Masch WR, Shampain K, et al. MRI assessment of hepatocellular carcinoma after local-regional therapy: a comprehensive review. Radiol Imaging Cancer 2020;2:e190024.
14. Shampain KL, Hackett CE, Towfighi S, et al. SBRT for HCC: Overview of technique and treatment response assessment. Abdom Radiol (NY) 2021;46:3615-24.
15. Mendiratta-Lala M, Aslam A, Maturen KE, et al. LI-RADS Treatment response algorithm: performance and diagnostic accuracy with radiologic-pathologic explant correlation in patients with sbrt-treated hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2022;112:704-14.
16. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009;49:1185-93.
17. Chen G, Jiao D, Peng S, et al. Peritumoral abnormalities on dynamic-enhanced CT after brachytherapy for hepatic malignancies: local progression or benign changes? Eur Radiol 2022;32:7307-19.
18. Vincenzi B, Di Maio M, Silletta M, et al. Prognostic relevance of objective response according to easl criteria and mrecist criteria in hepatocellular carcinoma patients treated with loco-regional therapies: a literature-based meta-analysis. PLoS One 2015;10:e0133488.
19. Zhou M, Zhang C, Nie J, et al. Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria. Front Oncol 2021;11:764189.
20. Prajapati HJ, Spivey JR, Hanish SI, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 2013;24:965-73.
21. Ghosn M, Derbel H, Kharrat R, et al. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Interv Imaging 2021;102:35-44.
22. Wang D, Gaba RC, Jin B, et al. Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma. Radiology 2014;272:587-97.
23. Ippolito D, Fior D, Bonaffini PA, et al. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol 2014;83:1665-71.
24. Kanamoto M, Miyati T, Terashima K, Suga D, Fuwa N. Preliminary study of apparent diffusion coefficient assessment after ion beam therapy for hepatocellular carcinoma. Radiol Phys Technol 2016;9:233-9.
25. Yu JI, Park HC, Lim DH, et al. The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 2014;89:814-21.
26. Cao Y, Cuneo KC, Evans J, Ten Haken RK, Chang DT, Lawrence TS. Is apparent diffusion coefficient established as an imaging biomarker for stereotactic body radiation therapy assessment in hepatocellular carcinoma? Cancer J 2023;29:238-42.
27. Lo CH, Huang WY, Hsiang CW, et al. Prognostic significance of apparent diffusion coefficient in hepatocellular carcinoma patients treated with stereotactic ablative radiotherapy. Sci Rep 2019;9:14157.
28. Qiong L, Jie Z, Zhong Z, et al. Detection of hepatocellular carcinoma in a population at risk: iodine-enhanced multidetector CT and/or gadoxetic acid-enhanced 3.0 T MRI. BMJ Open 2022;12:e058461.
29. Pfeiffer D, Parakh A, Patino M, Kambadakone A, Rummeny EJ, Sahani DV. Iodine material density images in dual-energy CT: quantification of contrast uptake and washout in HCC. Abdom Radiol (NY) 2018;43:3317-23.
30. Bargellini I, Crocetti L, Turini FM, et al. Response assessment by volumetric iodine uptake measurement: preliminary experience in patients with intermediate-advanced hepatocellular carcinoma treated with Yttrium-90 radioembolization. Cardiovasc Intervent Radiol 2018;41:1373-83.
31. Thaiss WM, Haberland U, Kaufmann S, et al. Dose optimization of perfusion-derived response assessment in hepatocellular carcinoma treated with transarterial chemoembolization: comparison of volume perfusion CT and iodine concentration. Acad Radiol 2019;26:1154-63.
32. Patel R, Aslam A, Parikh ND, et al. Updates on LI-RADS treatment response criteria for hepatocellular carcinoma: focusing on MRI. J Magn Reson Imaging 2023;57:1641-54.
33. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology 2018;68:723-50.
34. Lin H, Wu H, Cong N, Liu B, Liu C, Han D. Transarterial chemoembolization followed by radiotherapy versus sandwich treatment for unresectable or ablative hepatocellular carcinoma. Technol Cancer Res Treat 2020;19:1533033820983799.
35. Buckstein M, Kim E, Özbek U, et al. Combination transarterial chemoembolization and stereotactic body radiation therapy for unresectable single large hepatocellular carcinoma: results from a prospective Phase 2 trial. Int J Radiat Oncol Biol Phys 2022;114:221-30.
36. Ning C, Zhang X, Wang Y, et al. Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2024;118:1461-71.
37. Cozzi L, Dinapoli N, Fogliata A, et al. Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer 2017;17:829.
38. Park JW, Lee H, Hong H, Seong J. Efficacy of radiomics in predicting oncologic outcome of liver-directed combined radiotherapy in locally advanced hepatocellular carcinoma. Cancers (Basel) 2023;15:5405.
39. Wei L, Owen D, Rosen B, et al. A deep survival interpretable radiomics model of hepatocellular carcinoma patients. Phys Med 2021;82:295-305.
40. Wang L, Yan D, Shen L, Xie Y, Yan S. Prognostic value of a CT radiomics-based nomogram for the overall survival of patients with nonmetastatic BCLC stage C hepatocellular carcinoma after stereotactic body radiotherapy. J Oncol 2023;2023:1554599.
41. Wu K, Shui Y, Sun W, Lin S, Pang H. Utility of Radiomics for predicting patient survival in hepatocellular carcinoma with portal vein tumor thrombosis treated with stereotactic body radiotherapy. Front Oncol 2020;10:569435.
42. Wu K, Shui Y, Sun W, Lin S, Pang H. Utility of radiomics for predicting patient survival in hepatocellular carcinoma with portal vein tumor thrombosis treated with stereotactic body radiotherapy. Front Oncol 2020;10:569435.
43. Shen PC, Huang WY, Dai YH, et al. Radiomics-based predictive model of radiation-induced liver disease in hepatocellular carcinoma patients receiving stereo-tactic body radiotherapy. Biomedicines 2022;10:597.
44. Onuoha E, Smith AD, Cannon R, Khushman M, Kim H. Perfusion change of hepatocellular carcinoma during atezolizumab plus bevacizumab treatment: a pilot study. J Gastrointest Cancer 2023;54:776-81.
45. Choi JY, Yu JI, Park HC, et al. The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus. Liver Transpl 2017;23:545-51.
46. Montazeri SA, De la Garza-Ramos C, Lewis AR, et al. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging 2022;49:3892-7.
47. Wang YF, Dai YH, Lin CS, et al. Clinical outcome and pathologic correlation of stereotactic body radiation therapy as a bridge to transplantation for advanced hepatocellular carcinoma: a case series. Radiat Oncol 2021;16:15.
48. Garg R, Foley K, Movahedi B, et al. Outcomes after stereotactic body radiation therapy as a bridging modality to liver transplantation for hepatocellular carcinoma. Adv Radiat Oncol 2021;6:100559.
